Compare MRVI & NBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRVI | NBB |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.8M | 446.2M |
| IPO Year | 2020 | 2010 |
| Metric | MRVI | NBB |
|---|---|---|
| Price | $2.83 | $15.66 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.13 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 58.0K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $185,743,000.00 | N/A |
| Revenue This Year | $12.44 | N/A |
| Revenue Next Year | $7.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.67 | $14.52 |
| 52 Week High | $4.11 | $16.62 |
| Indicator | MRVI | NBB |
|---|---|---|
| Relative Strength Index (RSI) | 33.50 | 49.96 |
| Support Level | $2.57 | $15.47 |
| Resistance Level | $2.88 | $15.99 |
| Average True Range (ATR) | 0.17 | 0.24 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 3.42 | 80.65 |
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests a majority of its assets in a diversified portfolio of taxable municipal securities.